Integer (ITGR) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
6 Apr, 2026Executive summary
The annual meeting is scheduled for May 20, 2026, with voting on key proposals including director elections, auditor ratification, executive compensation, and a new omnibus incentive plan.
Shareholders can vote online, by phone, mail, or in person, with materials provided primarily via internet access to reduce costs and environmental impact.
2025 saw 8% sales growth to $1.854 billion, $221 million in operating income, and significant investments in acquisitions, capital expenditures, and share repurchases.
Voting matters and shareholder proposals
Election of 11 directors for a one-year term.
Ratification of Deloitte & Touche LLP as independent auditor for 2026.
Advisory vote on executive compensation (say-on-pay).
Approval of the 2026 Omnibus Incentive Plan, replacing the 2021 plan and authorizing 1,000,000 new shares plus rollover shares.
Board recommends voting FOR all proposals.
Board of directors and corporate governance
10 of 11 director nominees are independent; strong focus on board refreshment and diversity of skills.
Board committees (Audit, Compensation, Governance, Technology) are fully independent.
Annual board, committee, and individual director evaluations; robust orientation and continuing education.
No poison pill, no supermajority voting, and stockholders have the right to act by written consent.
Latest events from Integer
- Leadership transition set amid robust growth and minimal tariff impact, with strategy unchanged.ITGR
Bank of America 2025 Healthcare Conference9 Jul 2026 - 2025 outlook features robust organic growth, margin expansion, and enhanced vertical integration.ITGR
KeyBanc Annual Health Care Forum 20259 Jul 2026 - Double-digit 2024 growth, strategic acquisitions, and strong 2025 outlook with expanding margins.ITGR
Q4 20248 Jul 2026 - Q1 2025 sales up 7%, adjusted EPS up 15%, GAAP net loss from $46.7M debt expense.ITGR
Q1 20258 Jul 2026 - Strategic review and robust pipeline position the business for above-market growth by 2027.ITGR
Bank of America Global Healthcare Conference 20268 Jul 2026 - Strategic review underway; growth delayed to late 2026 amid EP market shifts and disciplined cost control.ITGR
Truist Securities MedTech Conference 202616 Jun 2026 - Temporary product headwinds in 2026 are expected to give way to above-market growth in 2027.ITGR
2026 KeyBanc Capital Markets Healthcare Forum12 May 2026 - 2026 outlook lowered on product headwinds; strategic review and share buybacks underway.ITGR
Q1 20261 May 2026 - 2025 saw 8% sales and 21% EPS growth; 2026 guidance is stable with strong long-term prospects.ITGR
Q4 20259 Apr 2026